No Data
No Data
Rakuauria Pharmaceuticals, Renascience, and others
<2586> The number of shares to be issued from the large exercise of the 15th subscription rights (with exercise price adjustment clause) is 3.37 million shares. <2934> Application for approval regarding the extension of the submission deadline for the J Frontier securities report. <4572> The start of the dose expansion part of the phase 1b trial of AS-1763 BTK inhibitor drug by Carna Bio. <4579> Obtained sales approval for Tegoprazan, a Rakulia drug for gastric acid secretion inhibition, in Columbia. <4888> Stella Pharma.
G.C. Planning, Fanpep, and others
<3727> APLIX completes the acquisition of its own shares <4073> Ji Shii planned to sell shares outside the exchange, 0.05 million shares <4881> Fan Pep started research on the progress of next-generation formulation technology for antibody-induced peptides (animal testing using monkeys, etc.) in the late phase <7361> HCH completes the acquisition of its own shares
Human Creation Holdings: Supplementary financial information for the third quarter of the fiscal year ending in September 2024.
Human Creation Holdings: Short announcement of consolidated financial results for the third quarter of the fiscal year ending September 2024 (Japanese standard)
HUMAN CREATION HOLDINGS: Quarterly Report - Eighth Quarter 2 (2024/01/01 to 2024/03/31)
HUMAN CREATION HOLDINGS: Confirmation letter
No Data